Clinical Trial Update: Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia

View source ↗

Summary

Post-authorization safety study of Renvela (sevelamer carbonate) in chronic kidney disease patients not on dialysis with hyperphosphatemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• Renvela (sevelamer carbonate)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Hyperphosphataemia, Chronic Kidney Disease | Status: COMPLETED